Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

m6A modification of lipoyltransferase 1 inhibits bladder cancer progression by activating cuproptosis

Oncogene (2024)Cite this article

Subjects

Abstract

Cuproptosis, a cell death process caused by copper ions, is mediated by protein lipidation related to lipoic acid metabolism. There is a close connection between cuproptosis and the progression and prognosis of various tumors. Here, we identified lipoyltransferase 1 (LIPT1), a key gene related to cuproptosis, was downregulated in bladder cancer (BLCA) and was associated with unfavorable patient prognosis. Restoring the LIPT1 expression in BLCA cells suppressed the proliferation and promoted cuproptosis. Moreover, the consequences of RNA sequencing and Bodipy staining showed that the metabolic pathway mediated by LIPT1 inhibited the accumulation of lipid droplets in cells, disrupted endoplasmic reticulum (ER) homeostasis, and promoted cell apoptosis. Additionally, overexpression of LIPT1 not only repressed the proliferation rate of BLCA cells in vitro but also in vivo. Mechanistically, YTH N6-Methyladenosine RNA Binding Protein F2 (YTHDF2) promoted the degradation of LIPT1 mRNA in a m6A-dependent manner. In summary, these conclusions reveal that LIPT1 promotes cuprotosis and ER stress to inhibit the progression of BLCA, indicating that LIPT1 will provide a powerful treatment direction and drug target for treating BLCA.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The cuproptosis-related gene LIPTI inhibited BLCA progression and was related to the overall survival of BLCA patients.
Fig. 2: Overexpression of LIPT1 inhibited the proliferation of BLCA cells.
Fig. 3: Overexpression of LIPT1 enhanced cuproptosis.
Fig. 4: YTHDF2 mediated mRNA degradation of LIPT1 in a m6A-dependent manner.
Fig. 5: YTHDF2 inhibited cuproptosis and promoted proliferation by targeting LIPT1 in BLCA.
Fig. 6: LIPT1 promoted ER stress-mediated cell apoptosis.
Fig. 7: Enhanced endoplasmic reticulum stress contributed to the inhibition of BLCA proliferation induced by LIPT1.

Similar content being viewed by others

Data availability

RNA-sequencing are available at the NCBl Sequence Read Archive (SRA) under the accession number PRJNA1130104.

References

  1. Richters A, Aben KKH, Kiemeney L. The global burden of urinary bladder cancer: an update. World J Urol. 2020;38:1895–904. https://doi.org/10.1007/s00345-019-02984-4.

    Article  PubMed  Google Scholar 

  2. Compérat E, Amin MB, Cathomas R, Choudhury A, De Santis M, Kamat A, et al. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet (Lond, Engl). 2022;400:1712–21. https://doi.org/10.1016/s0140-6736(22)01188-6.

    Article  Google Scholar 

  3. Grayson M. Bladder cancer. Nature. 2017;551:S33. https://doi.org/10.1038/551S33a.

    Article  CAS  PubMed  Google Scholar 

  4. Chen L, Min J, Wang F. Copper homeostasis and cuproptosis in health and disease. Signal Transduct Target Ther. 2022;7:378. https://doi.org/10.1038/s41392-022-01229-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Fukai T, Ushio-Fukai M, Kaplan JH. Copper transporters and copper chaperones: roles in cardiovascular physiology and disease. Am J Physiol Cell Physiol. 2018;315:C186–c201. https://doi.org/10.1152/ajpcell.00132.2018.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Sun L, Zhang Y, Yang B, Sun S, Zhang P, Luo Z, et al. Lactylation of METTL16 promotes cuproptosis via m(6)A-modification on FDX1 mRNA in gastric cancer. Nat Commun. 2023;14:6523. https://doi.org/10.1038/s41467-023-42025-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kardos J, Héja L, Simon Á, Jablonkai I, Kovács R, Jemnitz K. Copper signalling: causes and consequences. Cell Commun Signal: CCS. 2018;16:71. https://doi.org/10.1186/s12964-018-0277-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Xiao Y, Wang T, Song X, Yang D, Chu Q, Kang YJ. Copper promotion of myocardial regeneration. Exp Biol Med (Maywood, NJ). 2020;245:911–21. https://doi.org/10.1177/1535370220911604.

    Article  CAS  Google Scholar 

  9. Sensi SL, Granzotto A, Siotto M, Squitti R. Copper and Zinc Dysregulation in Alzheimer’s Disease. Trends Pharmacol Sci. 2018;39:1049–63. https://doi.org/10.1016/j.tips.2018.10.001.

    Article  CAS  PubMed  Google Scholar 

  10. Rihel J. Copper on the brain. Nat Chem Biol. 2018;14:638–9. https://doi.org/10.1038/s41589-018-0089-1.

    Article  CAS  PubMed  Google Scholar 

  11. Yang H, Liu CN, Wolf RM, Ralle M, Dev S, Pierson H, et al. Obesity is associated with copper elevation in serum and tissues. Metallomics: Integr Biometal Sci. 2019;11:1363–71. https://doi.org/10.1039/c9mt00148d.

    Article  CAS  Google Scholar 

  12. Møller LB, Mogensen M, Horn N. Molecular diagnosis of Menkes disease: genotype-phenotype correlation. Biochimie. 2009;91:1273–7. https://doi.org/10.1016/j.biochi.2009.05.011.

    Article  CAS  PubMed  Google Scholar 

  13. Członkowska A, Litwin T, Dusek P, Ferenci P, Lutsenko S, Medici V, et al. Wilson disease. Nat Rev Dis Prim. 2018;4:21. https://doi.org/10.1038/s41572-018-0018-3.

    Article  PubMed  Google Scholar 

  14. Noda Y, Asada M, Kubota M, Maesako M, Watanabe K, Uemura M, et al. Copper enhances APP dimerization and promotes Aβ production. Neurosci Lett. 2013;547:10–5. https://doi.org/10.1016/j.neulet.2013.04.057.

    Article  CAS  PubMed  Google Scholar 

  15. Tong X, Tang R, Xiao M, Xu J, Wang W, Zhang B, et al. Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. J Hematol Oncol. 2022;15:174. https://doi.org/10.1186/s13045-022-01392-3.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Denoyer D, Masaldan S, La Fontaine S, Cater MA. Targeting copper in cancer therapy: ‘Copper That Cancer. Metallomics: Integr Biometal Sci. 2015;7:1459–76. https://doi.org/10.1039/c5mt00149h.

    Article  CAS  Google Scholar 

  17. Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science (N.Y., NY). 2022;375:1254–61. https://doi.org/10.1126/science.abf0529.

    Article  CAS  Google Scholar 

  18. Xie J, Yang Y, Gao Y, He J. Cuproptosis: mechanisms and links with cancers. Mol cancer. 2023;22:46. https://doi.org/10.1186/s12943-023-01732-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Xu J, Hu Z, Cao H, Zhang H, Luo P, Zhang J, et al. Multi-omics pan-cancer study of cuproptosis core gene FDX1 and its role in kidney renal clear cell carcinoma. Front Immunol. 2022;13:981764. https://doi.org/10.3389/fimmu.2022.981764.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Wen H, Qu C, Wang Z, Gao H, Liu W, Wang H, et al. Cuproptosis enhances docetaxel chemosensitivity by inhibiting autophagy via the DLAT/mTOR pathway in prostate cancer. FASEB J: Off Publ Federation Am Societies Exp Biol. 2023;37:e23145. https://doi.org/10.1096/fj.202300980R.

    Article  CAS  Google Scholar 

  21. Yang W, Wang Y, Huang Y, Yu J, Wang T, Li C, et al. 4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to promote cuproptosis in colorectal cancer. Biomed Pharmacother = Biomedecine pharmacotherapie. 2023;159:114301. https://doi.org/10.1016/j.biopha.2023.114301.

    Article  CAS  PubMed  Google Scholar 

  22. Song W, Yang K, Luo J, Gao Z, Gao Y. Dysregulation of USP18/FTO/PYCR1 signaling network promotes bladder cancer development and progression. Aging. 2021;13:3909–25. https://doi.org/10.18632/aging.202359.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Li J, Xie H, Ying Y, Chen H, Yan H, He L, et al. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer. Mol cancer. 2020;19:152. https://doi.org/10.1186/s12943-020-01267-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Gao Q, Zheng J, Ni Z, Sun P, Yang C, Cheng M, et al. The m(6)A Methylation-Regulated AFF4 Promotes Self-Renewal of Bladder Cancer Stem Cells. Stem cells Int. 2020;2020:8849218. https://doi.org/10.1155/2020/8849218.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. An Y, Duan H. The role of m6A RNA methylation in cancer metabolism. Mol cancer. 2022;21:14. https://doi.org/10.1186/s12943-022-01500-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Sano R, Reed JC. ER stress-induced cell death mechanisms. Biochimica et biophysica acta. 2013;1833:3460–70. https://doi.org/10.1016/j.bbamcr.2013.06.028.

    Article  CAS  PubMed  Google Scholar 

  27. Qiu B, Ackerman D, Sanchez DJ, Li B, Ochocki JD, Grazioli A, et al. HIF2α-Dependent Lipid Storage Promotes Endoplasmic Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma. Cancer Discov. 2015;5:652–67. https://doi.org/10.1158/2159-8290.Cd-14-1507.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Ozcan U, Ozcan L, Yilmaz E, Düvel K, Sahin M, Manning BD, et al. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol cell. 2008;29:541–51. https://doi.org/10.1016/j.molcel.2007.12.023.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Liu WQ, Lin WR, Yan L, Xu WH, Yang J. Copper homeostasis and cuproptosis in cancer immunity and therapy. Immunol Rev. 2024;321:211–27. https://doi.org/10.1111/imr.13276.

    Article  CAS  PubMed  Google Scholar 

  30. Liu H, Tang T. Pan-cancer genetic analysis of cuproptosis and copper metabolism-related gene set. Front Oncol. 2022;12:952290. https://doi.org/10.3389/fonc.2022.952290.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Song Q, Zhou R, Shu F, Fu W. Cuproptosis scoring system to predict the clinical outcome and immune response in bladder cancer. Front Immunol. 2022;13:958368. https://doi.org/10.3389/fimmu.2022.958368.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Barbieri I, Kouzarides T. Role of RNA modifications in cancer. Nat Rev Cancer. 2020;20:303–22. https://doi.org/10.1038/s41568-020-0253-2.

    Article  CAS  PubMed  Google Scholar 

  33. Deng X, Su R, Weng H, Huang H, Li Z, Chen J. RNA N(6)-methyladenosine modification in cancers: current status and perspectives. Cell Res. 2018;28:507–17. https://doi.org/10.1038/s41422-018-0034-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Wang T, Kong S, Tao M, Ju S. The potential role of RNA N6-methyladenosine in Cancer progression. Mol Cancer. 2020;19:88. https://doi.org/10.1186/s12943-020-01204-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Liu Q. Current Advances in N6-Methyladenosine Methylation Modification During Bladder Cancer. Front Genet. 2021;12:825109. https://doi.org/10.3389/fgene.2021.825109.

    Article  CAS  PubMed  Google Scholar 

  36. Liu L, Li H, Hu D, Wang Y, Shao W, Zhong J, et al. Insights into N6-methyladenosine and programmed cell death in cancer. Mol cancer. 2022;21:32. https://doi.org/10.1186/s12943-022-01508-w.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Chen X, Zhou X, Wang X. m(6)A binding protein YTHDF2 in cancer. Exp Hematol Oncol. 2022;11:21. https://doi.org/10.1186/s40164-022-00269-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Zhang L, Li Y, Zhou L, Zhou H, Ye L, Ou T, et al. The m6A Reader YTHDF2 Promotes Bladder Cancer Progression by Suppressing RIG-I-Mediated Immune Response. Cancer Res. 2023;83:1834–50. https://doi.org/10.1158/0008-5472.Can-22-2485.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Zhong Y, Zeng W, Chen Y, Zhu X. The effect of lipid metabolism on cuproptosis-inducing cancer therapy. Biomed Pharmacother = Biomedecine pharmacotherapie. 2024;172:116247. https://doi.org/10.1016/j.biopha.2024.116247.

    Article  CAS  PubMed  Google Scholar 

  40. Chen T, Liang L, Wang Y, Li X, Yang C. Ferroptosis and cuproptposis in kidney Diseases: dysfunction of cell metabolism. Apoptosis: Int J Program cell death. 2024;29:289–302. https://doi.org/10.1007/s10495-023-01928-z.

    Article  Google Scholar 

  41. Zhang W, Wang M, Liu B, Chen H, Tan J, Meng Q, et al. Glutathione Induced In situ Synthesis of Cu Single-Atom Nanozymes with Anaerobic Glycolysis Metabolism Interference for Boosting Cuproptosis. Angewandte Chemie (International ed in English) 2024:e202402397. https://doi.org/10.1002/anie.202402397.

  42. Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12:31–46. https://doi.org/10.1158/2159-8290.Cd-21-1059.

    Article  CAS  PubMed  Google Scholar 

  43. Zhou L, Du K, Dai Y, Zeng Y, Luo Y, Ren M, et al. Metabolic reprogramming based on RNA sequencing of gemcitabine-resistant cells reveals the FASN gene as a therapeutic for bladder cancer. J Transl Med. 2024;22:55. https://doi.org/10.1186/s12967-024-04867-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Ni M, Solmonson A, Pan C, Yang C, Li D, Notzon A, et al. Functional Assessment of Lipoyltransferase-1 Deficiency in Cells, Mice, and Humans. Cell Rep. 2019;27:1376–86.e6. https://doi.org/10.1016/j.celrep.2019.04.005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Kastaniotis AJ, Autio KJ, Kerätär JM, Monteuuis G, Mäkelä AM, Nair RR, et al. Mitochondrial fatty acid synthesis, fatty acids and mitochondrial physiology. Biochimica et biophysica acta Mol cell Biol lipids. 2017;1862:39–48. https://doi.org/10.1016/j.bbalip.2016.08.011.

    Article  CAS  Google Scholar 

  46. Zhou L, Luo Y, Liu Y, Zeng Y, Tong J, Li M, et al. Fatty Acid Oxidation Mediated by Malonyl-CoA Decarboxylase Represses Renal Cell Carcinoma Progression. Cancer Res. 2023;83:3920–39. https://doi.org/10.1158/0008-5472.Can-23-0969.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Wang W, Lu K, Jiang X, Wei Q, Zhu L, Wang X, et al. Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer. J Exp Clin Cancer Res: CR. 2023;42:142. https://doi.org/10.1186/s13046-023-02720-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Zhou L, Song Z, Hu J, Liu L, Hou Y, Zhang X, et al. ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3. Theranostics. 2021;11:841–60. https://doi.org/10.7150/thno.49384.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Park HJ, Son HJ, Sul OJ, Suh JH, Choi HS. 4-Phenylbutyric acid protects against lipopolysaccharide-induced bone loss by modulating autophagy in osteoclasts. Biochem Pharmacol. 2018;151:9–17. https://doi.org/10.1016/j.bcp.2018.02.019.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the National Natural Sciences Foundation of China (NO. 82173294 to C.H.G, NO. 82203099 to L.J.Z.), the Training Program for Middle-aged and Young Discipline Leaders of Health of Henan Province (NO. HNSWJW-2021004 to C.H.G.); the Key Program Jointly Built by Henan Province and the Ministry of Medical Science and Technology(NO.SBGJ202102127 to C.H.G. and SBGJ202102095 to F.Y.T.); the Training Program of Young and Middle-aged Health Science and Technology Innovation Excellent Youth (NO.YXKC2021033 to C.H.G.); the Program of International Training of High-level Talents of Henan Province (NO.202207 to C.H.G.); the Science and Technology Research and Development Plan Joint Foundation of Henan Province (NO. 222301420017 to C.H.G.); the Key Project of Research and Practice of Education and Teaching Reform of Zhengzhou University (NO. 2022ZZUJG082 to C.H.G.); the Professional Degree Graduate Quality Teaching Case Project of Henan Province (NO. YJS2023AL013 to C.H.G.); the Funding for Scientific Research and Innovation Team of The First Affiliated Hospital of Zhengzhou University (NO. QNCXTD2023023 to C.H.G.); the Key Technologies R & D Program of Henan Province (NO. 232102521032 to C.H.G.); the Basic Research Incubation Program for Young Teachers of Zhengzhou University (NO. JC21854035 to F.Y.T.); the Joint Construction Project between Medical Science and Technology Research Project of Henan Province (No. LHGJ20220335 to L.J.Z.); the Key Scientific Research projects of Colleges and Universities of Henan Province (NO. 24A320058 to F.Y.T.).

Author information

Author notes

  1. These authors contributed equally: Kaixuan Du, Yongbo Luo, Lei Zhang.

Authors and Affiliations

  1. Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China

    Kaixuan Du, Yongbo Luo, Youmiao Zeng, Yiheng Dai, Mengda Ren, Wenbang Pan, Yuanhao Liu, Lijie Zhou & Chaohui Gu

  2. Department of Urology, Henan Institute of Urology and Zhengzhou Key Laboratory for Molecular Biology of Urological Tumor Research, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China

    Kaixuan Du, Yongbo Luo, Youmiao Zeng, Yiheng Dai, Mengda Ren, Wenbang Pan, Yuanhao Liu, Lijie Zhou & Chaohui Gu

  3. Unit of Day Surgery Center, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China

    Kaixuan Du, Yongbo Luo, Youmiao Zeng, Yiheng Dai, Mengda Ren, Wenbang Pan, Yuanhao Liu, Lijie Zhou & Chaohui Gu

  4. Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China

    Lei Zhang

  5. Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China

    Fengyan Tian

Authors
  1. Kaixuan Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yongbo Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Youmiao Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yiheng Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mengda Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wenbang Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yuanhao Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Fengyan Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Lijie Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Chaohui Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

C.H.G., F.Y.T., and L.J.Z. conceived the study. K.X.D., Y.B.L. and L.Z. designed experiments. K.X.D., Y.B.L., and Y.M.Z. performed experiments. K.X.D., Y.B.L. and Y.H.D. assisted with animal experiments. M.D.R., Y.H.L., and W.B.P. helped to obtain BLCA patients’ clinical information. K.X.D., and Y.B.L. analyzed the data. K.X.D. wrote the manuscript and all authors reviewed and approved the manuscript for publication.

Corresponding authors

Correspondence to Fengyan Tian, Lijie Zhou or Chaohui Gu.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Du, K., Luo, Y., Zhang, L. et al. m6A modification of lipoyltransferase 1 inhibits bladder cancer progression by activating cuproptosis. Oncogene (2024). https://doi.org/10.1038/s41388-024-03139-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41388-024-03139-5

Search

Advanced search

Quick links